- Home
- ABVC vs NRXP Comparison
ABVC vs NRXP Comparison
Compare ABVC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- NRXP
- Stock Information
- Founded
- ABVC 2015
- NRXP 2015
- Country
- ABVC United States
- NRXP United States
- Employees
- ABVC N/A
- NRXP N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- NRXP Health Care
- Exchange
- ABVC Nasdaq
- NRXP Nasdaq
- Market Cap
- ABVC 52.1M
- NRXP 58.5M
- IPO Year
- ABVC N/A
- NRXP N/A
- Fundamental
- Price
- ABVC $2.77
- NRXP $3.05
- Analyst Decision
- ABVC
- NRXP Strong Buy
- Analyst Count
- ABVC 0
- NRXP 5
- Target Price
- ABVC N/A
- NRXP $31.40
- AVG Volume (30 Days)
- ABVC 84.1K
- NRXP 435.6K
- Earning Date
- ABVC 11-13-2025
- NRXP 11-13-2025
- Dividend Yield
- ABVC N/A
- NRXP N/A
- EPS Growth
- ABVC N/A
- NRXP N/A
- EPS
- ABVC N/A
- NRXP N/A
- Revenue
- ABVC $391,242.00
- NRXP N/A
- Revenue This Year
- ABVC $735.18
- NRXP N/A
- Revenue Next Year
- ABVC N/A
- NRXP $395.09
- P/E Ratio
- ABVC N/A
- NRXP N/A
- Revenue Growth
- ABVC 186.84
- NRXP N/A
- 52 Week Low
- ABVC $0.40
- NRXP $1.12
- 52 Week High
- ABVC $5.48
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- ABVC 47.60
- NRXP 41.65
- Support Level
- ABVC $2.86
- NRXP $3.05
- Resistance Level
- ABVC $3.05
- NRXP $3.32
- Average True Range (ATR)
- ABVC 0.15
- NRXP 0.22
- MACD
- ABVC -0.02
- NRXP -0.05
- Stochastic Oscillator
- ABVC 26.59
- NRXP 0.74
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.